256 related articles for article (PubMed ID: 32844683)
1. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
Bruno AS; Willson JL; Opalinska JM; Nelson JJ; Lunacsek OE; Stafkey-Mailey DR; Willey JP
Expert Rev Hematol; 2020 Sep; 13(9):1017-1025. PubMed ID: 32844683
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Mohty M; Knauf W; Romanus D; Corman S; Verleger K; Kwon Y; Cherepanov D; Cambron-Mellott MJ; Vikis HG; Gonzalez F; Gavini F; Ramasamy K
Eur J Haematol; 2020 Sep; 105(3):308-325. PubMed ID: 32418256
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Madduri D; Hagiwara M; Parikh K; Pelletier C; Delea TE; Kee A; Chari A
Future Oncol; 2021 Feb; 17(5):503-515. PubMed ID: 33522834
[No Abstract] [Full Text] [Related]
6. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
7. Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS).
Touzeau C; Quignot N; Meng J; Jiang H; Khachatryan A; Singh M; Taieb V; Chauny JV; Désaméricq G
Ann Hematol; 2021 Jul; 100(7):1825-1836. PubMed ID: 33884454
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.
Wang PF; Yee CW; Gorsh B; Zichlin ML; Paka P; Bhak RH; Boytsov N; Khanal A; Noman A; DerSarkissian M; Ferrante S; Duh MS
Leuk Lymphoma; 2023 Feb; 64(2):398-406. PubMed ID: 36408998
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
[TBL] [Abstract][Full Text] [Related]
10. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: practice patterns across Europe.
Raab MS; Cavo M; Delforge M; Driessen C; Fink L; Flinois A; Gonzalez-McQuire S; Safaei R; Karlin L; Mateos MV; Schoen P; Yong K
Br J Haematol; 2016 Oct; 175(1):66-76. PubMed ID: 27291397
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
14. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Willenbacher E; Weger R; Rochau U; Siebert U; Willenbacher W;
PLoS One; 2016; 11(3):e0147381. PubMed ID: 26937956
[TBL] [Abstract][Full Text] [Related]
15. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
16. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma.
Hlavacek P; Schepart A; Silverstein AR; Petrilla AA; Johnson W; Schroeder A
Future Oncol; 2023 Apr; 19(11):775-787. PubMed ID: 37132520
[TBL] [Abstract][Full Text] [Related]
17. Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non- Hispanic White race/ethnicity in the United States.
Buck T; Hartley-Brown MA; Efebera YA; Milner CP; Zonder JA; Richardson PG; Salinardi T; Rice MS
Haematologica; 2024 Jun; 109(6):1882-1892. PubMed ID: 38031762
[TBL] [Abstract][Full Text] [Related]
18. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E
Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797
[TBL] [Abstract][Full Text] [Related]
19. Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan.
Weil C; Gelerstein S; Sharman Moser S; Chodick G; Barit Ben-David N; Shalev V; Shofaniyeh I; Kamalov R; Meytes D
Leuk Res; 2019 Oct; 85():106219. PubMed ID: 31473468
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).
Jagannath S; Abonour R; Durie BGM; Gasparetto C; Hardin JW; Narang M; Terebelo HR; Toomey K; Wagner L; Srinivasan S; Kitali A; Yue L; Flick ED; Agarwal A; Rifkin RM
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):480-485.e3. PubMed ID: 29844008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
